Evidence map›Paper›PMID 30080861›Full record

ArticlePLoS biology2018

Centromeric signaling proteins boost G1 cyclin degradation and modulate cell size in budding yeast.

Joan M Martínez-Láinez, David F Moreno, Eva Parisi, Josep Clotet, Martí Aldea

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Mad3 modulates the GScience advances · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Joan M Martínez-LáinezInstitut de Biologia Molecular de Barcelona IBMB-CSIC, Barcelona, Catalonia, Spain.
David F MorenoInstitut de Biologia Molecular de Barcelona IBMB-CSIC, Barcelona, Catalonia, Spain.
Eva ParisiInstitut de Biologia Molecular de Barcelona IBMB-CSIC, Barcelona, Catalonia, Spain.
Josep ClotetDepartament de Ciències Bàsiques, Universitat Internacional de Catalunya, Barcelona, Spain.
Martí AldeaInstitut de Biologia Molecular de Barcelona IBMB-CSIC, Barcelona, Catalonia, Spain.ORCID 0000-0002-8710-5336
Universitat Internacional de Catalunya · ESInstitut de Biologia Molecular de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell size scales with ploidy in a great range of eukaryotes, but the underlying mechanisms remain unknown. Using various orthogonal single-cell approaches, we show that cell size increases linearly with centromere (CEN) copy number in budding yeast. This effect is due to a G1 delay mediated by increased degradation of Cln3, the most upstream G1 cyclin acting at Start, and specific centromeric signaling proteins, namely Mad3 and Bub3. Mad3 binds both Cln3 and Cdc4, the adaptor component of the Skp1/Cul1/F-box (SCF) complex that targets Cln3 for degradation, these interactions being essential for the CEN-dosage dependent effects on cell size. Our results reveal a pathway that modulates cell size as a function of CEN number, and we speculate that, in cooperation with other CEN-independent mechanisms, it could assist the cell to attain efficient mass/ploidy ratios.

Indexed as

Cell Cycle ProteinsCell DivisionCell EnlargementCell Growth ProcessesCentromereCyclin G1CyclinsG1 PhaseGene Expression Regulation, FungalMembrane GlycoproteinsNuclear ProteinsProteolysisSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSaccharomycetalesSignal TransductionBUB3 protein, S cerevisiaeCell Cycle ProteinsCyclin G1CyclinsMAD3 protein, S cerevisiaeMembrane GlycoproteinsNuclear ProteinsSaccharomyces cerevisiae Proteins

Identifiers

PMID30080861
PMCPMC6095599
OpenAlexW2887295021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.